A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

A phase 1b randomized study of the safety and immunological responses to vaccination with H4:IC31, H56:IC31, and BCG revaccination in Mycobacterium tuberculosis-uninfected adolescents in Cape Town, South Africa

Background: Tuberculosis (TB) remains the leading cause of infectious disease-related death. Recently, a trial of BCG revaccination and vaccination with H4:IC31, a recombinant protein vaccine, in South African adolescents (Aeras C-040-404) showed efficacy in preventing sustained QuantiFERON (QFT) co...

Full description

Bibliographic Details
Main Authors: Linda-Gail Bekker, One Dintwe, Andrew Fiore-Gartland, Keren Middelkoop, Julia Hutter, Anthony Williams, April K. Randhawa, Morten Ruhwald, Ingrid Kromann, Peter L. Andersen, Carlos A. DiazGranados, Kathryn T. Rutkowski, Dereck Tait, Maurine D. Miner, Erica Andersen-Nissen, Stephen C. De Rosa, Kelly E. Seaton, Georgia D. Tomaras, M. Juliana McElrath, Ann Ginsberg, James G. Kublin
Format: Article
Language:English
Published: Elsevier 2020-04-01
Series:EClinicalMedicine
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020300572

Internet

http://www.sciencedirect.com/science/article/pii/S2589537020300572

Similar Items